Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 396
Inquire Before Buying

Global Markets Direct's, ‘Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016', provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD)

  • The report reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Graft Versus Host Disease (GVHD) therapeutics and enlists all their major and minor projects

  • The report assesses Graft Versus Host Disease (GVHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD)

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Graft Versus Host Disease (GVHD) Overview 11
Therapeutics Development 12
Pipeline Products for Graft Versus Host Disease (GVHD) - Overview 12
Pipeline Products for Graft Versus Host Disease (GVHD) - Comparative Analysis 13
Graft Versus Host Disease (GVHD) - Therapeutics under Development by Companies 14
Graft Versus Host Disease (GVHD) - Therapeutics under Investigation by Universities/Institutes 19
Graft Versus Host Disease (GVHD) - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Graft Versus Host Disease (GVHD) - Products under Development by Companies 25
Graft Versus Host Disease (GVHD) - Products under Investigation by Universities/Institutes 30
Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development 31
AbbVie Inc 31
AbGenomics International, Inc. 32
Actelion Ltd 33
Alexion Pharmaceuticals Inc 34
Amunix Operating Inc. 35
Apceth GmbH & Co. KG 36
arGEN-X BV 37
Athersys, Inc. 38
Bellicum Pharmaceuticals, Inc. 39
Bio-Cancer Treatment International Limited 40
Biogen Inc 41
Bristol-Myers Squibb Company 42
Cantex Pharmaceuticals, Inc. 43
Capricor Therapeutics, Inc. 44
Cell2B S.A. 45
CellECT Bio, Inc. 46
Cynata Therapeutics Limited 47
Cytodyn Inc. 48
Dompe Farmaceutici S.p.A. 49
Dr. Falk Pharma GmbH 50
Escape Therapeutics, Inc. 51
F. Hoffmann-La Roche Ltd. 52
Fate Therapeutics, Inc. 53
Generon (Shanghai) Corporation Ltd. 54
Gilead Sciences, Inc. 55
GlaxoSmithKline Plc 56
Idera Pharmaceuticals, Inc. 57
ImmuNext, Inc. 58
Immunomedics, Inc. 59
Incyte Corporation 60
Kadmon Corporation, LLC 61
Kamada Ltd. 62
Kiadis Pharma N.V. 63
Kymab Limited 64
Kyorin Pharmaceutical Co., Ltd. 65
MacroGenics, Inc. 66
Mallinckrodt Plc 67
Medsenic 68
Mesoblast Limited 69
Millennium Pharmaceuticals Inc 70
Neopharm Ltd. 71
Nohla Therapeutics Inc. 72
Novartis AG 73
OncoImmune, Inc. 74
OSE Immunotherapeutics 75
Pharmicell Co., Ltd. 76
REGiMMUNE Corporation 77
Rigel Pharmaceuticals, Inc. 78
Sarepta Therapeutics, Inc. 79
Seattle Genetics, Inc. 80
Seres Therapeutics, Inc. 81
Sigmoid Pharma Limited 82
Spherium Biomed S.L. 83
Takeda Pharmaceutical Company Limited 84
Targazyme, Inc. 85
Therapix Biosciences Ltd. 86
Tobira Therapeutics, Inc. 87
Vault Pharma Inc. 88
Xenikos B.V. 89
ZIOPHARM Oncology, Inc. 90
Graft Versus Host Disease (GVHD) - Therapeutics Assessment 91
Assessment by Monotherapy Products 91
Assessment by Combination Products 92
Assessment by Target 93
Assessment by Mechanism of Action 97
Assessment by Route of Administration 101
Assessment by Molecule Type 103
Drug Profiles 105
abatacept - Drug Profile 105
AbGn-168H - Drug Profile 110
AGS-499 - Drug Profile 112
aldesleukin - Drug Profile 113
Alecmestencel-L - Drug Profile 115
alpha-1 proteinase inhibitor (human) - Drug Profile 116
ALXN-1007 - Drug Profile 120
AMX-342 - Drug Profile 122
anti-thymocyte globulin (rabbit) - Drug Profile 123
Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD - Drug Profile 125
Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile 126
ARGX-115 - Drug Profile 127
arsenic trioxide - Drug Profile 128
ATIR-101 - Drug Profile 129
BCT-200 - Drug Profile 133
begelomab - Drug Profile 134
Biologic to Activate IL-2 for Graft Versus Host Disease - Drug Profile 135
Biologics for Graft Versus Host Disease - Drug Profile 136
bortezomib - Drug Profile 137
BPX-501 - Drug Profile 145
brentuximab vedotin - Drug Profile 149
budesonide - Drug Profile 173
cannabidiol - Drug Profile 176
CAP-2003 - Drug Profile 177
CD-24Fc - Drug Profile 178
Cell Therapy for Graft Versus Host Disease - Drug Profile 179
Cell Therapy for Graft-Versus Host Disease - Drug Profile 180
Cellgram for Graft Versus Host Disease - Drug Profile 181
Cellular Immunotherapy for Acute Graft Versus Host Disease - Drug Profile 182
Cellular Immunotherapy for Autoimmune Diseases and Transplantation - Drug Profile 183
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 185
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 186
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 187
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 188
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 189
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 190
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 191
Cellular Immunotherapy for Graft Versus Host Disease and Multiple Myeloma - Drug Profile 192
cenicriviroc mesylate - Drug Profile 193
CRCBT-080004 - Drug Profile 200
CX-01 - Drug Profile 201
cyclosporine CR + cyclosporine IR - Drug Profile 203
CYP-001 - Drug Profile 204
entospletinib - Drug Profile 206
F-652 - Drug Profile 208
FR-104 - Drug Profile 209
Ha-7 - Drug Profile 212
ibrutinib - Drug Profile 213
ImmuneSafe - Drug Profile 238
ImmuStem - Drug Profile 239
IMO-8400 - Drug Profile 240
IT-603 - Drug Profile 246
IT-901 - Drug Profile 247
itacitinib adipate - Drug Profile 248
KD-025 - Drug Profile 251
KRP-203 - Drug Profile 255
KY-1005 - Drug Profile 257
MAX-16H5 - Drug Profile 258
MesoStem - Drug Profile 259
methoxsalen - Drug Profile 260
MGD-010 - Drug Profile 262
milatuzumab - Drug Profile 264
Monoclonal Antibody to Inhibit CD3 for Cardiovascular, CNS, Gastrointestinal, Immunological, Infectious and Metabolic Diseases - Drug Profile 266
natalizumab - Drug Profile 268
nilotinib - Drug Profile 272
obinutuzumab - Drug Profile 278
OCU-300 - Drug Profile 285
Oligonucleotide to Inhibit NFAT1 for GVHD - Drug Profile 286
panobinostat - Drug Profile 287
PF-05285401 - Drug Profile 295
ponesimod - Drug Profile 305
Preimplantation Factor - Drug Profile 307
PRO-140 - Drug Profile 308
ProTmune - Drug Profile 316
R-348 - Drug Profile 318
Recombinant Protein for Graft Versus Host Disease and Autoimmune Disorders - Drug Profile 320
Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis - Drug Profile 321
Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease - Drug Profile 322
remestemcel-L - Drug Profile 323
reparixin - Drug Profile 328
RGI-2001 - Drug Profile 331
RO-2959 - Drug Profile 333
rovalpituzumab tesirine - Drug Profile 334
ruxolitinib phosphate - Drug Profile 336
S-Graft - Drug Profile 347
SER-155 - Drug Profile 348
Small Molecule for Autoimmune Disorders, Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis - Drug Profile 349
Small Molecule to Inhibit Protein Kinase C Theta for Immunological Disorders and Multiple Sclerosis - Drug Profile 350
Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile 351
Small Molecules to Selectively Inhibit ROCK2 for Autoimmune Disorders - Drug Profile 352
sonidegib phosphate - Drug Profile 353
SP-12008 - Drug Profile 357
SYGN-305 - Drug Profile 358
Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease - Drug Profile 359
T-Guard - Drug Profile 360
TZ-101 - Drug Profile 362
vedolizumab - Drug Profile 365
VPI-101 - Drug Profile 369
ZL-1101 - Drug Profile 370
Graft Versus Host Disease (GVHD) - Dormant Projects 371
Graft Versus Host Disease (GVHD) - Discontinued Products 376
Graft Versus Host Disease (GVHD) - Product Development Milestones 377
Featured News & Press Releases 377
Appendix 388
Methodology 388
Coverage 388
Secondary Research 388
Primary Research 388
Expert Panel Validation 388
Contact Us 388
Disclaimer 389

List of Tables

Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2016 19
Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Development by Companies, H2 2016 (Contd..1) 22
Number of Products under Development by Companies, H2 2016 (Contd..2) 23
Number of Products under Development by Companies, H2 2016 (Contd..3) 24
Number of Products under Development by Companies, H2 2016 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H2 2016 27
Comparative Analysis by Late Stage Development, H2 2016 28
Comparative Analysis by Clinical Stage Development, H2 2016 29
Comparative Analysis by Early Stage Development, H2 2016 30
Comparative Analysis by Unknown Stage Development, H2 2016 31
Products under Development by Companies, H2 2016 32
Products under Development by Companies, H2 2016 (Contd..1) 33
Products under Development by Companies, H2 2016 (Contd..2) 34
Products under Development by Companies, H2 2016 (Contd..3) 35
Products under Development by Companies, H2 2016 (Contd..4) 36
Products under Investigation by Universities/Institutes, H2 2016 37
Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc, H2 2016 38
Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International, Inc., H2 2016 39
Graft Versus Host Disease (GVHD) - Pipeline by Actelion Ltd, H2 2016 40
Graft Versus Host Disease (GVHD) - Pipeline by Alexion Pharmaceuticals Inc, H2 2016 41
Graft Versus Host Disease (GVHD) - Pipeline by Amunix Operating Inc. , H2 2016 42
Graft Versus Host Disease (GVHD) - Pipeline by Apceth GmbH & Co. KG, H2 2016 43
Graft Versus Host Disease (GVHD) - Pipeline by arGEN-X BV, H2 2016 44
Graft Versus Host Disease (GVHD) - Pipeline by Athersys, Inc., H2 2016 45
Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 46
Graft Versus Host Disease (GVHD) - Pipeline by Bio-Cancer Treatment International Limited, H2 2016 47
Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc, H2 2016 48
Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Company, H2 2016 49
Graft Versus Host Disease (GVHD) - Pipeline by Cantex Pharmaceuticals, Inc., H2 2016 50
Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics, Inc., H2 2016 51
Graft Versus Host Disease (GVHD) - Pipeline by Cell2B S.A. , H2 2016 52
Graft Versus Host Disease (GVHD) - Pipeline by CellECT Bio, Inc., H2 2016 53
Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Limited, H2 2016 54
Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc., H2 2016 55
Graft Versus Host Disease (GVHD) - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 56
Graft Versus Host Disease (GVHD) - Pipeline by Dr. Falk Pharma GmbH, H2 2016 57
Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics, Inc., H2 2016 58
Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 59
Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics, Inc., H2 2016 60
Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016 61
Graft Versus Host Disease (GVHD) - Pipeline by Gilead Sciences, Inc., H2 2016 62
Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc, H2 2016 63
Graft Versus Host Disease (GVHD) - Pipeline by Idera Pharmaceuticals, Inc., H2 2016 64
Graft Versus Host Disease (GVHD) - Pipeline by ImmuNext, Inc., H2 2016 65
Graft Versus Host Disease (GVHD) - Pipeline by Immunomedics, Inc., H2 2016 66
Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corporation, H2 2016 67
Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corporation, LLC, H2 2016 68
Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd., H2 2016 69
Graft Versus Host Disease (GVHD) - Pipeline by Kiadis Pharma N.V., H2 2016 70
Graft Versus Host Disease (GVHD) - Pipeline by Kymab Limited, H2 2016 71
Graft Versus Host Disease (GVHD) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 72
Graft Versus Host Disease (GVHD) - Pipeline by MacroGenics, Inc., H2 2016 73
Graft Versus Host Disease (GVHD) - Pipeline by Mallinckrodt Plc, H2 2016 74
Graft Versus Host Disease (GVHD) - Pipeline by Medsenic, H2 2016 75
Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Limited, H2 2016 76
Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 77
Graft Versus Host Disease (GVHD) - Pipeline by Neopharm Ltd., H2 2016 78
Graft Versus Host Disease (GVHD) - Pipeline by Nohla Therapeutics Inc., H2 2016 79
Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG, H2 2016 80
Graft Versus Host Disease (GVHD) - Pipeline by OncoImmune, Inc., H2 2016 81
Graft Versus Host Disease (GVHD) - Pipeline by OSE Immunotherapeutics, H2 2016 82
Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co., Ltd., H2 2016 83
Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corporation, H2 2016 84
Graft Versus Host Disease (GVHD) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 85
Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics, Inc., H2 2016 86
Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics, Inc., H2 2016 87
Graft Versus Host Disease (GVHD) - Pipeline by Seres Therapeutics, Inc., H2 2016 88
Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Limited, H2 2016 89
Graft Versus Host Disease (GVHD) - Pipeline by Spherium Biomed S.L., H2 2016 90
Graft Versus Host Disease (GVHD) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 91
Graft Versus Host Disease (GVHD) - Pipeline by Targazyme, Inc., H2 2016 92
Graft Versus Host Disease (GVHD) - Pipeline by Therapix Biosciences Ltd., H2 2016 93
Graft Versus Host Disease (GVHD) - Pipeline by Tobira Therapeutics, Inc., H2 2016 94
Graft Versus Host Disease (GVHD) - Pipeline by Vault Pharma Inc., H2 2016 95
Graft Versus Host Disease (GVHD) - Pipeline by Xenikos B.V., H2 2016 96
Graft Versus Host Disease (GVHD) - Pipeline by ZIOPHARM Oncology, Inc., H2 2016 97
Assessment by Monotherapy Products, H2 2016 98
Assessment by Combination Products, H2 2016 99
Number of Products by Stage and Target, H2 2016 101
Number of Products by Stage and Mechanism of Action, H2 2016 105
Number of Products by Stage and Route of Administration, H2 2016 109
Number of Products by Stage and Molecule Type, H2 2016 111
Graft Versus Host Disease (GVHD) - Dormant Projects, H2 2016 378
Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..1), H2 2016 379
Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..2), H2 2016 380
Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..3), H2 2016 381
Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..4), H2 2016 382
Graft Versus Host Disease (GVHD) - Discontinued Products, H2 2016 383

List of Figures

Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2016 19
Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Investigation by Universities/Institutes, H2 2016 26
Comparative Analysis by Clinical Stage Development, H2 2016 29
Comparative Analysis by Early Stage Products, H2 2016 30
Assessment by Monotherapy Products, H2 2016 98
Number of Products by Top 10 Targets, H2 2016 100
Number of Products by Stage and Top 10 Targets, H2 2016 100
Number of Products by Top 10 Mechanism of Actions, H2 2016 104
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 104
Number of Products by Top 10 Routes of Administration, H2 2016 108
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 108
Number of Products by Top 10 Molecule Types, H2 2016 110
Number of Products by Stage and Top 10 Molecule Types, H2 2016 110
  • Post Operative Nausea And Vomiting - Pipeline Review, H2 2016
    Published: 07-Dec-2016        Price: US 2000 Onwards        Pages: 50
    Post Operative Nausea And Vomiting - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Operative Nausea And Vomiting - Pipeline Review, H2 2016, provides an overview of the Post Operative Nausea And Vomiting (Gastrointestinal) pipeline landscape. Postoperative nausea and vomiting (PONV) is one of the commonest complaints following anaesthesia, and can result in morbidity like wound ......
  • Global Brachytherapy Afterloaders, Brachytherapy Seeds Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 06-Dec-2016        Price: US 3480 Onwards        Pages: 118
    "Brachytherapy also known as internal radiotherapy, sealed source radiotherapy, curie therapy or endocurietherapy, is a form of radiotherapy where a sealed radiation source is placed inside or next to the area requiring treatment. Brachytherapy is commonly used as an effective treatment for cervical, prostate, breast, and skin cancer and can also be used to treat tumors in many other body sites. Brachytherapy Afterloaders, is kind of machine used in brachytherapy to deliverer radi......
  • United States Breast Implants and Sizer Market Report 2016
    Published: 05-Dec-2016        Price: US 3800 Onwards        Pages: 102
    Notes: Sales, means the sales volume of Breast Implants and Sizer Revenue, means the sales value of Breast Implants and Sizer This report studies sales (consumption) of Breast Implants and Sizer in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Allergan - Natrelle - CEREPLAS - EuroSilicone - Laboratoires Arion - Mentor - Nagor - Polytech Health ......
  • Hypothyroidism - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 29
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypothyroidism - Pipeline Review, H2 2016, provides an overview of the Hypothyroidism (Hormonal Disorders) pipeline landscape.Hypothyroidism (underactive thyroid) is a condition in which thyroid gland doesn't produce enough of certain important hormones. Signs and symptom include fatigue, constipation, dry skin, puffy face, muscle weakness, muscle aches, tenderness and stiffness, pain and stiffness. Risk facto......
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 63
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenoleukodystrophy - Pipeline Review, H2 2016, provides an overview of the Adrenoleukodystrophy (Genetic Disorders) pipeline landscape.Adrenoleukodystrophy is a disorder that occurs most often in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. Abetalipoproteinemia is also a kind of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-......
  • Behcet Disease - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 80
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Behcet Disease - Pipeline Review, H2 2016, provides an overview of the Behcet Disease (Immunology) pipeline landscape.Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behçet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals (sex organs). More serious symptoms can include inflammation (swelling, heat,......
  • Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 63
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2016, provides an overview of the Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline landscape.Hypogonadotropic hypogonadism (HH) is a form of hypogonadism that is due to a problem with the pituitary gland or hypothalamus. HH is caused by a lack of hormones that normally stimulate the ovaries or testes like gonadotropin-releasing hor......
  • Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 53
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H2 2016, provides an overview of the Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline landscape.Homozygous familial hypercholesterolemia is a genetic disorder which is caused due to mutation from both parents. HoFH causes LDL cholesterol level to be very high. Symptoms include xanthelasmas, chest pain and sores on ......
  • Spinocerebellar Ataxia (SCA) - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 65
    Spinocerebellar Ataxia (SCA) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinocerebellar Ataxia (SCA) - Pipeline Review, H2 2016, provides an overview of the Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline landscape. Spinocerebellar ataxias (SCAs) are a group of inherited conditions that affect the brain and spinal cord causing progressive difficulty with coordination. ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs